Abstract OBJECTIVE: To investigate the clinical features of Mycoplasma pneumoniae pneumonia (MPP) among children of different ages. METHODS: Retrospective analysis was performed on the clinical data of 112 children who were hospitalized due to MMP between January 2010 and December 2011. The children were divided into 3 groups according to their ages: infants (<3 years; n=20), preschool-aged children (≥3 years; n=41), and school-aged children (6-15.2 years; n=51). The three groups were compared in terms of their clinical symptoms, pulmonary signs, chest X-ray findings and laboratory test results. RESULTS: The infant group presented mainly with expectoration and wheezing, accompanied by low fever. They showed gastrointestinal symptoms as the most common extra-pulmonary manifestation and had evident pulmonary signs. The majority of the school-aged children group presented with high fever and a severe dry cough, and wheezing was seen in several of them. They showed rash as the most common extra-pulmonary manifestation and had slight pulmonary signs. The symptoms of the preschool-aged children group were in between. In the infant and preschool-aged children groups, most showed bronchopneumonia on chest X-ray, while in the school-aged children group, chest X-rays mostly showed segmental parenchymatous infiltration. The infant group had a higher lymphocyte count than the school-aged children group, while the school-aged children group had a higher serum C-reactive protein level than the infant group. CONCLUSIONS: The clinical features of MPP are different among children of different ages, especially between infants and school-aged children.
XIA Yu,WU Can-Kui,TANG Yin-Yan et al. Differences in the clinical features of Mycoplasma pneumoniae pneumonia among children of different ages[J]. CJCP, 2013, 15(3): 179-182.
XIA Yu,WU Can-Kui,TANG Yin-Yan et al. Differences in the clinical features of Mycoplasma pneumoniae pneumonia among children of different ages[J]. CJCP, 2013, 15(3): 179-182.
［2］Nolevaux G, Bessaci-Kabouya K, Villenet N, Andreoletti L, Laplanche D, Carquin J, et al. Epidemiological and clinical study of Mycoplasma pneumoniae respiratory infections in children hospitalized in a pediatric ward between 1999 and 2005 at the Reims University Hospital［J］. Arch Pediatr, 2008, 15(11): 1630-1636.
［3］Lee KY. Pediatric respiratory infections by Mycoplasma peneumoniae［J］. Expert Rev Anti Infect Ther, 2008, 6(4): 509-521.
［6］Defilippi A, Silvestri M, Tacchella A, Giacchino R, Melioli G, Di Marco E, et al. Epidemiology and clinical features of Mycoplasma pneumoniae infection in children［J］. Resoir Med, 2008, 102(12): 1762-1768.
［8］Principi N, Esposito S, Blasi F, Allegra L; Mowqli study group. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections ［J］. Clin Infect Dis, 2001, 32(9): 1281-1289.
［9］Waites KB, Talkington DE. Mycoplasma pneumoniae and its role as a human pathogen［J］. Clin Microbiol Rev, 2004, 17(4): 697-728.
［10］Denny FW, Talor-Robinson D, Allison AC. The role of thmus-dependent immunity in Mycoplasma pulmonis infection of mice［J］.J Med Microbiol, 1972, 5(3): 327-336.
［11］Shimizu T, Kida Y, Kuwanok. A dipalmitoylated lipoprotein from Mycoplasma pneumoniae activates NF-kappa B through TLR1,TLR2 and TLR6［J］. J Immunol, 2005, 175(7): 4641-4646.
［12］Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB, et al. Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae Pneumonia model: a micobiologic, histologic, immunologic, and respiratory plethymographic profile［J］. Infect Immun, 2001, 69(6): 3869-3876.
